Whether fracture prediction tools developed for the management of osteoporosis can be used in chronic kidney disease (CKD) is poorly known. We aimed to compare the performance of fracture prediction tools in non‐CKD and CKD. We analyzed CARTaGENE, a population‐based survey of 40‐year‐old to 69‐year‐old individuals recruited between 2009 and 2010. Renal function was assessed using baseline creatinine and categorized according to Kidney Disease Improving Global Outcomes (KDIGO) guidelines (non‐CKD, stage 2, stage 3). Individuals without creatinine measurements or with advanced CKD (stage 4 or 5;​ prevalence <0.25%) were excluded. Predicted 5‐year fracture probabilities (using Fracture Risk Assessment Tool [FRAX], QFracture, and Garvan) were computed at baseline. Fracture incidence (major fracture [MOF] or any fracture) was evaluated in administrative databases from recruitment to March 2016. Discrimination (hazard ratios [HRs] per standard deviation [SD] increase in Cox models;​ c‐statistics) and calibration (standardized incidence ratios [SIRs] before and after recalibration) were assessed in each CKD strata. We included 19,393 individuals (9522 non‐CKD;​ 9114 stage 2;​ 757 stage 3). A total of 830 patients had any fracture during follow‐up, including 352 MOF. FRAX (HR = 1.89 [1.63–2.20] non‐CKD;​ 1.64 [1.41–1.91] stage 2;​ 1.76 [1.10–2.82] stage 3) and QFracture (HR = 1.90 [1.62–2.22] non‐CKD;​ 1.57 [1.35–1.82] stage 2;​ 1.86 [1.19–2.91] stage 3) discriminated MOF similarly in non‐CKD and CKD. In contrast, the discrimination of Garvan for any fracture tended to be lower in CKD stage 3 compared to non‐CKD and CKD stage 2 (HR = 1.36 [1.22–1.52] non‐CKD;​ 1.34 [1.20–1.50] stage 2;​ 1.11 [0.79–1.55] stage 3). Before recalibration, FRAX globally overestimated fracture risk while QFracture and Garvan globally underestimated fracture risk. After recalibration, FRAX and QFracture were adequately calibrated for MOF in all CKD strata whereas Garvan tended to underestimate any fracture risk in CKD stage 3 (SIR = 1.31 [0.95–1.81]). In conclusion, the discrimination and calibration of FRAX and QFracture is similar in non‐CKD and CKD. Garvan may have a lower discrimination in CKD stage 3 and underestimate fracture risk in these patients.